Biotechnology

The Korean biopharma giant is leveraging its biosimilar success to fund a major push into cutting-edge cancer therapies and advanced drug platforms.

Flashpoint Therapeutics appoints an FDA-approved drug developer as CSO, a strategic move to accelerate its groundbreaking structural nanomedicine platform.

Reimbursements are falling and costs are rising, but top allergy practices are boosting revenue by 22%. A new report reveals their data-driven secrets.

From developing neonatal ventilators to pivotal COVID vaccine research, a San Antonio institute marks 85 years on the front lines of global health.

MIT economist Andrew Lo joins the Global Coalition for Adaptive Research, bringing Wall Street strategies to revolutionize clinical trials for rare diseases.

A new alliance in healthcare marketing merges pharmaceutical expertise with provider-side insights, leveraging AI and big data to fix a fragmented system.

With its lead cancer therapy pelareorep showing promise, Oncolytics hires veteran execs to navigate the final hurdles of clinical trials and regulatory approval.

Adial Pharmaceuticals files a key patent to protect its personalized Alcohol Use Disorder drug, AD04, until 2045, signaling a new era for addiction medicine.

With a promising brain injury drug and no approved rivals, Oragenics heads to a tax-haven investor summit to secure funding for its next critical phase.

A novel biologic therapy from Immunis shows significant gains in walking speed for obese seniors, hinting at a new frontier in treating age-related decline.

With major funding and a seasoned CEO, Caldera Therapeutics is advancing a first-in-class bispecific antibody into the clinic for inflammatory bowel disease.

As BD enters a new growth phase with interim leadership, the MedTech giant brings in Shawn Bevec, whose unique background bridges lab science and Wall Street.

A new AI solution promises to automate a critical manufacturing step, tackling costly errors and downtime that plague the life sciences industry.

With new data showing six-month efficacy and a unique liquid formula, Galderma's Relfydess is poised to challenge established players in the neuromodulator space.

Dr. Toby Kiers wins the Tyler Prize for her work on fungi, as her NGO launches a new program to legally protect these vital underground ecosystems.

A new partnership aims to bring a revolutionary, disease-modifying stem cell therapy for knee osteoarthritis to millions of patients in Greater China.

With new funding from BroadOak Capital Partners, Axol Bioscience is set to expand its revolutionary iPSC-based disease models in the US market.

Moving beyond hype, ArisGlobal's record growth and enterprise adoption of its NavaX AI show the pharmaceutical industry is now operationalizing AI at scale.

With a new finance head, the non-profit plans to launch a breakthrough vitamin A product in Africa, blending philanthropy with commercial strategy.

The biopharma firm projects massive sales from its current drugs and bets big on a new Alzheimer's therapy, signaling a pivotal year of growth and innovation.